Cathie Wood, CEO of Ark Invest, invests in innovative companies like Intellia Therapeutics, a gene editing biotech currently ranked 25th on Ark’s holdings list. The company’s shares are up 41%, driven by promising candidates lonvo-z and nex-z targeting rare diseases. Despite a recent FDA clinical hold setback, Intellia Therapeutics shows potential in addressing unmet medical needs. However, investing in gene editing biotechs like Intellia remains risky due to regulatory challenges and limited market traction. Investors should weigh the risks before considering buying stock in Intellia Therapeutics.

Read more at Nasdaq: This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?